Genome engineering using CRSPR-Cas9

The problem

Cellular reprogramming holds enormous potential across sectors including food & agriculture, but limited tools have hindered accuracy, efficiency, and dexterity.

The solution

CRISPR Cas9 enables precision genome reprogramming of cells.

Our engagement

Participated in the Series B financing round alongside F-Prime Capital. Active role in the Board of Caribou prior to the company’s pre-IPO financing round in 2021. Pre-IPO investors included Farallon Capital Management, PFM Health Sciences, Ridgeback Capital Investments, AbbVie Ventures, Adage Capital Partners LP, Avego Bioscience Capital, Avidity Partners, Invus, Janus Henderson Investors, LifeSci Venture Partners, The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP), Monashee Investment Management, LLC, Point72, and funds managed by Tekla Capital Management LLC.